Mary Pat Gallagher, MD, of NYU Langone Health, outlines why young individuals should be vaccinated against COVID-19 and Finnish data on increased rates of type 1 diabetes (T1D) seen during the pandemic.
Data out of Finland suggest increased incidence of type 1 diabetes may not necessarily be due to infection with SARS-CoV-2—the virus that causes COVID-19—but may have been due to another factor of the pandemic, said Mary Pat Gallagher, MD, a pediatric endocrinologist at NYU Langone Health.
Transcript:
With COVID-19 vaccines approved for teens and children over 12, how might this push to get these populations vaccinated benefit children with diabetes?
I am strongly in support of vaccination against preventable illnesses. I think that it would be advisable for patients to receive the COVID-19 vaccines as soon as the FDA allows it. I think that it is a challenge for our kids under 12, who are unable to be vaccinated currently, who may then have different access to different venues. For instance, there are shows starting to open up and just interactive activities that they might be able to take part in, which right now they're getting frequent nasal swabs to make sure they can continue to participate. But to get back to normal for them, and be able to really participate in school, especially when the summer is over, I really would love for them to be able to be vaccinated, so they could get back to a more normal way of life. And that's not just specific to children with diabetes, it's everyone.
Research shows pandemic mitigation efforts may have led to more cases of diabetic ketoacidosis (DKA) at the time of type 1 diabetes (T1D) diagnosis due in part to parents' COVID-19 exposure concerns. What needs to happen in the future to improve outcomes for these patients should more pandemics occur?
I think that is a big lesson learned from what we saw happen here, and I'm sure diabetes is not the only diagnosis for which this was an issue—that delay in seeking care was a problem. We saw a lot of excess mortality in New York City during the height of the pandemic, and while much of that was probably due to undiagnosed COVID-19 deaths at home, it may also have been excess deaths from cardiac disease from people who didn't go in when they had chest pain or stroke symptoms. It's possible that those people wouldn't have died had they sought care more rapidly.
I think that we have to look at what worked during this pandemic and try not to lose sight of how valuable the ability to see patients virtually is. You can get a lot of information just by looking at a person on camera. You can see if they have any respiratory distress. You can really do more than you think you can in assessing them. I would say that we need to try to make sure that we close the digital divide, because people don't have the same equal access to virtual care. That is an issue, right? First we have to remember it exists and it works really well for certain issues, especially, but it's better than no care 100% of the time. Then we have to try to work on making access to that type of care more widespread.
Do you have any closing thoughts you would like to share?
One of the most interesting pieces of data that has come out is the data from Finland, which has the highest incidence of T1D in the world. There is a strong genetic predisposition to T1D. They documented an actual increase in T1D incidence in their population, which is very interesting because they did not have a very significant incidence of SARS-CoV-2 infection. They did some seroprevalence studies—which we're not sure how to interpret, in all fairness—but it was extremely low in the newly diagnosed patients. So it suggests that there may be some other phenomenon that did occur in the same period, but that this increase in frequency—so not just the incidence of DKA at diagnosis, but the increase in diagnosis of diabetes, T1D—that it might be related to something other than a personal infection with SARS-CoV-2, but in some way related to other things that were going on during the pandemic. It's fascinating, I think.
Bridging Education Gaps in Treatment for Scarring Alopecia With Innovative Approaches
March 28th 2025Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Strategies for Improving Patient Access to Dermatology Care
March 22nd 2025Elizabeth Jones, MD, FAAD, highlights the persistent issue of insurance companies favoring expensive, newer medications over equally effective generics in dermatology, emphasizing the time-consuming prior authorization process and advocating for patient partnerships and systemic improvements.
Read More
Redefining Long COVID Care With Personalized Treatment
March 20th 2025To mark the 5-year anniversary of the COVID pandemic, The American Journal of Managed Care® spoke with Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City.
Read More